Clinical Trial Update: Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating a combination of GX-188E vaccination, GX-I7, and pembrolizumab in patients with advanced, resectable HPV16/18-positive head and ne…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• GX-188E (GX-188E DNA vaccine)
• GX-I7
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Yonsei University | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING